{
    "complex": false,
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "replication_method": "physical",
    "ucits": true,
    "type": "ETF",
    "complex_factors": [],
    "classification": "non-complex",
    "supporting_data": "The iShares Nasdaq US Biotechnology UCITS ETF is classified as non-complex under MiFID II based on the following analysis: 1. Physical Replication: The fund uses physical replication to track the NASDAQ Biotechnology Index, as explicitly stated in the PRIIPs KID ('Methodology: Replicated'). 2. No Leverage or Inverse Exposure: There is no mention of leverage, inverse strategies, or amplified returns in the KIID or PRIIPs KID. 3. Minimal Derivative Usage: While the KIID mentions the potential use of financial derivative instruments (FDIs) to help achieve the investment objective, the PRIIPs KID clarifies that the product structure is 'Physical,' indicating derivatives are not a core component of the strategy. The mention of FDIs in the KIID is likely a standard disclosure for UCITS funds, not an indication of active derivative usage. 4. Straightforward Index Tracking: The fund tracks a well-known, liquid equity index (NASDAQ Biotechnology Index) with clear eligibility criteria and weighting methodology. 5. No Complex Underlying Assets: The fund invests in liquid, transparent equity securities of biotechnology and pharmaceutical companies, with no mention of complex structured products or illiquid assets. 6. Risk Profile: The fund's risk rating is 6/7, which is moderate and aligns with the inherent risks of equity investing. There are no disclosures suggesting the fund is unsuitable for retail investors or requires specialist knowledge. 7. Costs and Charges: The fund has a simple fee structure (0.35% TER) with no performance fees or complex cost arrangements. 8. Counterparty Risk: The PRIIPs KID mentions counterparty risk, but this is standard for UCITS ETFs and does not indicate complexity. The risk is limited to the safekeeping of assets and does not involve derivative counterparty exposure. 9. Securities Lending: The fund engages in short-term secured lending, but this is a common practice among ETFs and does not introduce complexity. The revenue from securities lending is shared between the fund and BlackRock, but this does not alter the fund's risk profile. 10. UCITS Compliance: The fund is UCITS-compliant, which inherently limits the use of complex strategies and derivatives. The PRIIPs KID does not include a 'comprehension warning,' further supporting the non-complex classification.",
    "confidence": 95
}